CD BioGlyco provides comprehensive and precise analysis services for Ery-Est within the pharmaceutical field. Our focus encompasses qualitative and quantitative detection of this compound across diverse pharmaceutical formulations, along with thorough assessments of its physicochemical properties. Leveraging our expertise, we ensure accurate identification and characterization of Ery-Est, supporting extensive research applications ranging from pharmaceutical development to biomarker studies.
Ery-Est, the lauryl sulfate ester of propionyl erythromycin, is a topical macrolide antibiotic with broad-spectrum antibacterial activity. It enters the bacterial cell membrane and precisely binds to the 50S subunit of the bacterial ribosome, disrupting the synthesis of bacterial proteins. The bacteriostatic or bactericidal effect of Ery-Est is determined by the drug concentration at the infection site and the susceptibility of the specific organism.
Fig.1 The structure of Ery-Est. (CD BioGlyco)
CD BioGlyco's Ery-Est analysis service primarily focuses on qualitative and quantitative analysis. Our method guarantees a meticulous assessment of Ery-Est, encompassing considerations related to its identity and concentration. The service encompasses precise analytical methods that contribute to the accurate characterization of this macrolide antibiotic, providing valuable insights for pharmaceutical development and quality assurance.
For the analysis of Ery-Est, our methods are available for several preparations.
Our analysis service includes but is not limited
Fig.2 The standard content of Ery-Est analysis. (CD BioGlyco)
Technology: Plaque assay, Drug cytotoxicity assay, Immunofluorescence staining assay, RNase digestion assay and RT-qPCR
Journal: Frontiers in Cellular and Infection Microbiology
IF: 5.7
Published: 2022
Results: In this study, it was found that Ery-Est, a lauryl sulfate ester of propionyl erythromycin (Ery), effectively inhibited HCoV-OC43 infection in various host cells. Ery and Ery-Est are macrolide antibiotics used for bacterial infections, and Ery-Est showed significant antiviral activity against HCoV-OC43. Plaque reduction and immunofluorescence assays demonstrated dose-dependent inhibition, with Ery-Est exhibiting robust suppression of HCoV-OC43 infection in different host cells without apparent toxicity. This suggests its potential as an antiviral agent.
Fig.3 The anti-HCoV-OC43 activity of Ery-Est. (Wang, et al., 2022)
CD BioGlyco offers a comprehensive Ery-Est analysis service, moreover, we also offer a suite of Pharmaceutical and Biological Analyses. Tailored to address the varied requirements of Pharmaceutical Research, our services guarantee precise and dependable outcomes across a range of applications. From qualitative and quantitative analysis of Ery-Est to broader pharmaceutical analysis, our research team and advanced analytical methods contribute to the success of drug development and quality control processes. Trust CD BioGlyco for precise and tailored service in the field of pharmaceutical analysis and please feel free to contact us!
Reference
